Mechanisms of Diastolic Dysfunction in Heart Failure

Trends in Cardiovascular Medicine

Volumn 16, Issue 8, 2006, Pages 273-279

  Borlaug, Barry A ^a   Kass, David A ^b  

^a Mayo Clinic   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; IRBESARTAN;

CELL ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; DIASTOLE; DIASTOLIC BLOOD PRESSURE; EXTRACELLULAR MATRIX; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART RIGHT ATRIUM; HUMAN; PATHOPHYSIOLOGY; PERICARDIUM; PRIORITY JOURNAL; REVIEW;

DIASTOLE; EXTRACELLULAR MATRIX; HEART; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; STROKE VOLUME;

EID: 33749991812     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2006.05.003     Document Type: Review

References (58)

1. Ahmed S., Clark L., Pennington W., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
2. Asif M., Egan J., Vasan S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 97 (2000) 2809-2813
3. Badenhorst D., Maseko M., Tsotetsi O., et al. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res 57 (2003) 632-641
4. Baicu C., Zile M., Aurigemma G., et al. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 111 (2005) 2306-2312
5. Borlaug B., Melenovsky V., Shively L., et al. Impaired systolic and vasodilator reserve in patients with heart failure and a normal ejection fraction. Circulation 112 (2005) 2841
6. Borlaug B., Melenovsky V., Marhin T., et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112 (2005) 2642-2649
7. Carson P., Massie B., McKelvie R., et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 11 (2005) 576-585
8. Dauterman K., Pak P., Maughan W., et al. Contribution of external forces to left ventricular diastolic pressure. Implications for the clinical use of the Starling law. Ann Intern Med 122 (1995) 737-742
9. Del Monte F., Harding S., Dec G., et al. Targeting phospholamban by gene transfer in human heart failure. Circulation 105 (2002) 904-907
10. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
11. Frank K., Bolck B., Brixius K., et al. Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 97 (2002) I72-I78 (suppl 1)
12. Fukuta H., Sane D., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
13. Granzier H., and Labeit S. Cardiac titin: an adjustable multi-functional spring. J Physiol 541 (2002) 335-342
14. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99 (1999) 641-648
15. He K., Dickstein M., Sabbah H., et al. Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res 64 (2004) 72-83
16. Higashi M., Shimokawa H., Hattori T., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93 (2003) 767-775
17. Hoshijima M., Ikeda Y., Iwanaga Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8 (2002) 864-871
18. Hundley W., Kitzman D., Morgan T., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38 (2001) 796-802
19. Kass D. Assessment of diastolic dysfunction. Invasive modalities. Cardiol Clin 18 (2000) 571-586
20. Kass D., and Solaro R. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113 (2006) 305-315
21. Kass D., Midei M., Brinker J., et al. Influence of coronary occlusion during PTCA on end-systolic and end-diastolic pressure-volume relations in humans. Circulation 81 (1990) 447-460
22. Kass D., Wolff M., Ting C., et al. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann Intern Med 119 (1993) 466-473
23. Kass D., Bronzwaer J., and Paulus W. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 94 (2004) 1533-1542
24. Kawaguchi M., Hay I., Fetics B., et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107 (2003) 714-720
25. Kitzman D., Little W., Brubaker P., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 (2002) 2144-2150
26. Kuwahara F., Kai H., Tokuda K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002) 130-135
27. Labeit D., Watanabe K., Witt C., et al. Calcium-dependent molecular spring elements in the giant protein titin. Proc Natl Acad Sci U S A 100 (2003) 13716-13721
28. Lahmers S., Wu Y., Call D., et al. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res 94 (2004) 505-513
29. Leite-Moreira A., and Correia-Pinto J. Load as an acute determinant of end-diastolic pressure-volume relation. Am J Physiol Heart Circ Physiol 280 (2001) H51-H59
30. Little W., Zile M., Kitzman D., et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 (2005) 191-195
31. Liu C., Ting C., Lawrence W., et al. Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation 88 (1993) 1893-1906
32. MacKenna D., Omens J., McCulloch A., et al. Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. Am J Physiol 266 (1994) H1007-H1018
33. Marx S., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365-376
34. Matsumoto T., Wada A., Tsutamoto T., et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107 (2003) 2555-2558
35. Melenovsky V., Borlaug B., Hay I., et al. Atrial dilation/dysfunction: a defining feature of heart failure with normal ejection fraction (HFnEF). Circulation 112 (2005) 3535
36. Miyamoto M., Del Monte F., Schmidt U., et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 97 (2000) 793-798
37. Netticadan T., Temsah R., Kawabata K., et al. Sarcoplasmic reticulum Ca(2+)/Calmodulin-dependent protein kinase is altered in heart failure. Circ Res 86 (2000) 596-605
38. 2+ movement. Basic Res Cardiol 97 (2002) I91-I95 (suppl 1)
39. Oh J., Hatle L., Tajik A., et al. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 47 (2006) 500-506
40. Pak P., Maughan L., Baughman K., et al. Marked discordance between dynamic and passive diastolic pressure-volume relations in idiopathic hypertrophic cardiomyopathy. Circulation 94 (1996) 52-60
41. Paolocci N., Tavazzi B., Biondi R., et al. Metalloproteinase inhibitor counters high-energy phosphate depletion and AMP deaminase activity enhancing ventricular diastolic compliance in subacute heart failure. J Pharmacol Exp Ther 317 (2006) 506-513
42. Senzaki H., Fetics B., Chen C., et al. Comparison of ventricular pressure relaxation assessments in human heart failure: quantitative influence on load and drug sensitivity analysis. J Am Coll Cardiol 34 (1999) 1529-1536
43. Senzaki H., Paolocci N., Gluzband Y., et al. Beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 86 (2000) 807-815
44. Stroud J., Baicu C., Barnes M., et al. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol 282 (2002) H2324-H2335
45. Takemoto Y., Barnes M., Seward J., et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol 96 (2005) 832-836
46. Takimoto E., Soergel D., Janssen P., et al. Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res 94 (2004) 496-504
47. Takimoto E., Champion H., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214-222
48. Vahebi S., Kobayashi T., Warren C., et al. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res 96 (2005) 740-747
49. VanHeerebeek L., Borbely A., Niessen H., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006) 1966-1973
50. Wang T., Levy D., Benjamin E., et al. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138 (2003) 907-916
51. Wolska B., Vijayan K., Arteaga G., et al. Expression of slow skeletal troponin I in adult transgenic mouse heart muscle reduces the force decline observed during acidic conditions. J Physiol 536 (2001) 863-870
52. Wu Y., Cazorla O., Labeit D., et al. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 32 (2000) 2151-2162
53. Wu Y., Bell S., Trombitas K., et al. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 106 (2002) 1384-1389
54. Yamamoto K., Masuyama T., Sakata Y., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55 (2002) 76-82
55. Yamasaki R., Wu Y., McNabb M., et al. Protein kinase A phosphorylates titin's cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ Res 90 (2002) 1181-1188
56. Yu C., Lin H., Yang H., et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 105 (2002) 1195-1201
57. Yusuf S., Pfeffer M., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
58. Zile M., Baicu C., and Gaasch W. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004) 1953-1959